Cargando…

A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study

We aimed to explore a new treatment model for type 2 diabetes mellitus (DM) based on rhythm regulation under the framework of psychosomatic medicine. Using psychotropics as rhythm regulators, 178 patients with DM were evaluated and divided into three groups: the antidiabetic treatment group (AT grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Wenjiao, Sun, Xueli, Tang, Nie, Zhang, Yaoyin, Luo, Fang, Zhu, Min, Xia, Wei, Zhou, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852565/
https://www.ncbi.nlm.nih.gov/pubmed/36658428
http://dx.doi.org/10.1038/s41598-023-28278-9
_version_ 1784872672408109056
author Min, Wenjiao
Sun, Xueli
Tang, Nie
Zhang, Yaoyin
Luo, Fang
Zhu, Min
Xia, Wei
Zhou, Bo
author_facet Min, Wenjiao
Sun, Xueli
Tang, Nie
Zhang, Yaoyin
Luo, Fang
Zhu, Min
Xia, Wei
Zhou, Bo
author_sort Min, Wenjiao
collection PubMed
description We aimed to explore a new treatment model for type 2 diabetes mellitus (DM) based on rhythm regulation under the framework of psychosomatic medicine. Using psychotropics as rhythm regulators, 178 patients with DM were evaluated and divided into three groups: the antidiabetic treatment group (AT group), psychotropic treatment group (PT group), and combined antidiabetic + psychotropic treatment group (combined group), for a course of 16 weeks. The West China Psychiatry Association (WCPA) Somatic Symptom Classification Scale (SSCS) was used to evaluate each patient. The levels of hormones in the hypothalamic–pituitary–adrenal (HPA) and hypothalamic-pituitary-thyroid axes and of blood glucose and glycosylated hemoglobin (HbA1c) were evaluated both before and after treatment. After the treatment, the blood glucose and HbA1c levels in all three groups were lower than those at baseline. Furthermore, the incidence of the abnormal HPA axis in the PT group was significantly decreased (P = 0.003), while the incidence of the abnormal HPA axis in the combined group was 0.0%. The five factor scores of the SSCS in the PT and combined groups after treatment were both significantly low (P < 0.01). Both the incidence of abnormal neuroendocrine axes and SSCS scores in the AT group showed no significant difference before and after treatment. “Blood glucose control + rhythm regulation” should be considered as optimised treatment goals for DM. Moreover, some psychotropics could be used as biorhythm regulators, which have good potential value for clinical application. Clinical trial registration number: ChiCTR1800019064. Name of trial registration: Reinterpretation of mechanism and the optimization of treatment for non-infectious chronic diseases under the “stress-dysrhythmia” theory hypothesis. The full trial protocol can be accessed at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).
format Online
Article
Text
id pubmed-9852565
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98525652023-01-21 A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study Min, Wenjiao Sun, Xueli Tang, Nie Zhang, Yaoyin Luo, Fang Zhu, Min Xia, Wei Zhou, Bo Sci Rep Article We aimed to explore a new treatment model for type 2 diabetes mellitus (DM) based on rhythm regulation under the framework of psychosomatic medicine. Using psychotropics as rhythm regulators, 178 patients with DM were evaluated and divided into three groups: the antidiabetic treatment group (AT group), psychotropic treatment group (PT group), and combined antidiabetic + psychotropic treatment group (combined group), for a course of 16 weeks. The West China Psychiatry Association (WCPA) Somatic Symptom Classification Scale (SSCS) was used to evaluate each patient. The levels of hormones in the hypothalamic–pituitary–adrenal (HPA) and hypothalamic-pituitary-thyroid axes and of blood glucose and glycosylated hemoglobin (HbA1c) were evaluated both before and after treatment. After the treatment, the blood glucose and HbA1c levels in all three groups were lower than those at baseline. Furthermore, the incidence of the abnormal HPA axis in the PT group was significantly decreased (P = 0.003), while the incidence of the abnormal HPA axis in the combined group was 0.0%. The five factor scores of the SSCS in the PT and combined groups after treatment were both significantly low (P < 0.01). Both the incidence of abnormal neuroendocrine axes and SSCS scores in the AT group showed no significant difference before and after treatment. “Blood glucose control + rhythm regulation” should be considered as optimised treatment goals for DM. Moreover, some psychotropics could be used as biorhythm regulators, which have good potential value for clinical application. Clinical trial registration number: ChiCTR1800019064. Name of trial registration: Reinterpretation of mechanism and the optimization of treatment for non-infectious chronic diseases under the “stress-dysrhythmia” theory hypothesis. The full trial protocol can be accessed at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/). Nature Publishing Group UK 2023-01-19 /pmc/articles/PMC9852565/ /pubmed/36658428 http://dx.doi.org/10.1038/s41598-023-28278-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Min, Wenjiao
Sun, Xueli
Tang, Nie
Zhang, Yaoyin
Luo, Fang
Zhu, Min
Xia, Wei
Zhou, Bo
A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title_full A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title_fullStr A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title_full_unstemmed A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title_short A new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
title_sort new model for the treatment of type 2 diabetes mellitus based on rhythm regulations under the framework of psychosomatic medicine: a real-world study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852565/
https://www.ncbi.nlm.nih.gov/pubmed/36658428
http://dx.doi.org/10.1038/s41598-023-28278-9
work_keys_str_mv AT minwenjiao anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT sunxueli anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT tangnie anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhangyaoyin anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT luofang anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhumin anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT xiawei anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhoubo anewmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT minwenjiao newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT sunxueli newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT tangnie newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhangyaoyin newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT luofang newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhumin newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT xiawei newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy
AT zhoubo newmodelforthetreatmentoftype2diabetesmellitusbasedonrhythmregulationsundertheframeworkofpsychosomaticmedicinearealworldstudy